Nektar beats on earnings–more importantly FDA accepts company’s new opioid for review
I'm on vacation through August 26. I'm trying to use this down time to catch up on earnings results that I missed during the very busy second quarter earning season. After the market close on Wednesday, August 8, Nectar Therapeutics (NKTR) reported earnings of $5.33 a...
Buying Albermarle today for my Jubak Picks Portfolio
Who says the collapse of the Turkish lira and of the Turkish stock market isn't good news for anyone? While it's certainly true that the troubles in Turkey--which have become worse as the country's relationship with the United States has tipped for mild disagreement...
My cash position in Jubak Picks portfolio is up to 35%, roughly
Lots of activity in this portfolio since I last reported on its cash level. There have been sells of MGM Resorts International (MGM), Starbucks (SBUX), and Arco Dorados (ARCO). I've made buys of Microsoft (MSFT), Lionsgate Entertainment (LGF/A), and Valero (VLO). At...
New catalysts lining up for MGM Resorts–I’ll hold in my Jubak Picks Portfolio for the moment of recognition
Shares of MGM Resorts International (MGM) peaked for 2018 (so far) at $38.03 on January 29, 2018 and since then the trend has been brutally downward. The stock's 50-day moving average broke below its 200-day moving average (a moment that technical analysts called the...
FDA delivers less than half a loaf to INCY and LLY in approving Olumiant
Today the U.S. Food & Drug Administration did finally approve Baricitinib, now known as Olumiant, for the treatment of moderately-to-severely active rheumatoid arthritis. But the approval carries more restrictions than expected. The FDA approved only the 2...
Nvidia crushes earnings; stock falls after hours
Okay, if you're a trader I sort of understand selling Nvidia (NVDA) after today's earnings report: Sell on the news; How can it get better? How long can the company keep it up? After all, the stock closed today just pennies below it's all time high. (It's the...
Special premium report Part 1: My 2018 earnings boom profit strategy–and two picks
With the report of first quarter earnings season from Netflix (NFLX) on Monday, April 16, we’ve moved into the heart of earnings season. In most quarters traders began putting on plays for earnings announcements a few weeks before reporting starts. And they’ll keep making new bets over the next three weeks or so. In most quarters buying shares or options on companies about to report makes profitable sense. But this strategy is likely to be even more rewarding this year
Monday buy of SolarEdge Technologies in my Jubak Picks portfolio
I've been looking for a way out of this investing puzzle for a while and I think I've finally found one. SolarEdge Technologies (SEDG). I'm adding these shares to my Jubak Picks Portfolio on Monday. And I'll be buying call options on these shares in my Volatility...
New calculation: Current cash position in Jubak Picks Portfolio
In response to reader requests from here on out I’m going to calculate an approximate cash position (I won’t do all the nitty gritty to include things like the latest dividend payouts but the number should be reasonably close) after each buy and sell. The latest action in the portfolio was the April 3, 2018 sell of Freeport McMoRan Copper & Gold. After that sale the cash position in the portfolio is 31.6%. That’s up from 27.2% at the end of December 2017.
Selling copper pick Freeport McMoran on fears of U.S./China tariff war
Freeport McMoRan Copper and Gold (FCX) was the third and last copper stock I added to my portfolios back in January 12, 2018--after Southern Copper (SCCO) and First Quantum Minerals (FQMLF). I added so much copper since copper prices were soaring in 2017--up 30%--and...Jim’s Stock Alerts
Download Jim’s eBook for Free
